Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Presage Biosciences
With
National Institutes of Health (NIH)
National Cancer Institute (NCI)
Fred Hutchinson Cancer Center
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
18 years of age or over
Has enlarged lymph node(s) highly suspicious of lymphoma; or has been diagnosed with lymphoma but is untreated; or has persistent recurrent, or progressive lymphoma
At least one enlarged lymph node that is considered accessible for percutaneous injection by the investigator and that is at least 2 cm in longest dimension.
ECOG performance status of 0-2 (or a Karnofsky performance status of \>50%).
Labs required for enrollment: Absolute neutrophil count \> 1000/mm3, platelet count \> 50,000/mm3, hematocrit \> 25%, creatinine \<3.0 mg/dl, total bilirubin \<4.0 mg/dl, SGOT and SGPT less than five times the institutional upper limits of normal.
You may not be if
Lymphoma patients in which the delay of surgery until the lymph node resection date or other factors associated with the study are not feasible.
Patients with central nervous system disease.
Any therapy that is potentially immunosuppressive or has anticancer activity in the 4 weeks prior to device microinjection.
Patients with active fungal, viral, or bacterial infections
Pregnant women.
Inability to give informed consent.
Clareo Health | Feasibility of Assessing Lymphoma Response to Precise Local Injection of Candidate Chemotherapy Agents
